PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32777075-0	2020	HLA DRB1*15:01-DQB1*06:02-restricted human CD4+ T-cells are selectively activated with amoxicillin-peptide adducts.	Amoxicillin	87-98	major histocompatibility complex, class II, DR beta 1	Homo sapiens	0-8	
32777075-6	2020	This study aimed to (1) investigate whether amoxicillin-modified HLA-DRB1*15:01-DQB1*06:02 binding peptides selectively activate DILI patient T-cells and (2) define the nature of the T-cell response with respective to antigen structure.	Amoxicillin	44-55	major histocompatibility complex, class II, DR beta 1	Homo sapiens	65-73	
32777075-11	2020	The T-cells response was HLA class II-restricted and the amoxicillin-modified peptides bound selectively to HLA-DRB1*15:01 and/or DQB1*06:02.	Amoxicillin	57-68	major histocompatibility complex, class II, DR beta 1	Homo sapiens	108-116	
32777075-12	2020	To conclude, we show that amoxicillin-modified peptides bind to both components of the risk haplotype to stimulate DILI patient T-cells and describe the importance of the position of nucleophilic lysine residue in the HLA binding peptide sequence.	Amoxicillin	26-37	major histocompatibility complex, class II, DR beta 1	Homo sapiens	218-221	
30664875-8	2019	Among amoxicillin- and clavulanate-associated cases of European ancestry, rs2476601 doubled the risk for DILI among those with the HLA risk alleles A*02:01 and DRB1*15:01.	Amoxicillin	6-17	major histocompatibility complex, class II, DR beta 1	Homo sapiens	160-164